AR093425A1 - Cepa de lactobacillus rhamnosus para reducir la acumulacion de grasa corporal - Google Patents

Cepa de lactobacillus rhamnosus para reducir la acumulacion de grasa corporal

Info

Publication number
AR093425A1
AR093425A1 ARP130104120A ARP130104120A AR093425A1 AR 093425 A1 AR093425 A1 AR 093425A1 AR P130104120 A ARP130104120 A AR P130104120A AR P130104120 A ARP130104120 A AR P130104120A AR 093425 A1 AR093425 A1 AR 093425A1
Authority
AR
Argentina
Prior art keywords
lactobacillus rhamnosus
cepa
fat accumulation
body fat
reduce body
Prior art date
Application number
ARP130104120A
Other languages
English (en)
Inventor
Genoves Martinez Salvador
Ortiz Soriano Pepa
Llopis Pla Silvia
Gonzalez Martinez Nuria
Martorell Guerola Patricia
Grompone Gianfranco
Ramon Vidal Daniel
Original Assignee
Gervais Danone Sa
Biopolis SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone Sa, Biopolis SL filed Critical Gervais Danone Sa
Publication of AR093425A1 publication Critical patent/AR093425A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Utilización de la cepa CNCM I-3690 de Lactobacillus rhamnosus para la reducción de la acumulación de grasa en el cuerpo y el tratamiento de trastornos que son resultados de esa acumulación, tales como el sobrepeso, la obesidad y los trastornos relacionados con la obesidad. Reivindicación 5: La cepa CNCM I-3690 de Lactobacillus rhamnosus para el uso que se indica en la reivindicación 4, que se caracteriza porque la mencionada composición es un producto alimenticio o un suplemento alimenticio.
ARP130104120A 2012-11-12 2013-11-08 Cepa de lactobacillus rhamnosus para reducir la acumulacion de grasa corporal AR093425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/056344 WO2014072771A1 (en) 2012-11-12 2012-11-12 Lactobacillus rhamnosus strain for reducing body fat accumulation

Publications (1)

Publication Number Publication Date
AR093425A1 true AR093425A1 (es) 2015-06-10

Family

ID=47356248

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104120A AR093425A1 (es) 2012-11-12 2013-11-08 Cepa de lactobacillus rhamnosus para reducir la acumulacion de grasa corporal

Country Status (10)

Country Link
US (1) US9855304B2 (es)
EP (1) EP2925333A1 (es)
JP (1) JP2016507216A (es)
CN (1) CN104955467A (es)
AR (1) AR093425A1 (es)
BR (1) BR112015010639A2 (es)
CA (1) CA2890574A1 (es)
MX (1) MX2015005897A (es)
RU (1) RU2015122728A (es)
WO (1) WO2014072771A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101864347B1 (ko) * 2017-09-06 2018-06-05 주식회사 지놈앤컴퍼니 락토바실러스 람노수스 lm1019 균주 및 이를 포함하는 비만 또는 당뇨병 예방 및 치료용 조성물
CN109757730B (zh) * 2019-01-31 2021-06-04 山东环亿生物科技有限公司 一种具有降血脂、血压以及血糖的组合物及其制备方法
CN113750113B (zh) * 2020-06-01 2022-12-02 山东新时代药业有限公司 一种益生菌和益生元的组合物及其应用
CN112442463A (zh) * 2020-11-25 2021-03-05 北京科拓恒通生物技术股份有限公司 鼠李糖乳杆菌Probio-M9及其制剂用于制备延长寿命制品的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001756B1 (en) * 2004-02-19 2006-02-21 Genmont Biotech Inc. Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity
KR100686557B1 (ko) 2004-08-16 2007-02-23 씨제이 주식회사 체지방 저하 기능성 락토바실러스 람노서스와 이를 함유한 식품
US20100216212A1 (en) 2005-07-26 2010-08-26 School Corp., Azabu Veterin Med. Educa'l Institu Anti-obesity agent and anti-obesity food
SE529185C2 (sv) 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
JP2009524640A (ja) * 2006-01-27 2009-07-02 ダニスコ エー／エス 肥満及びそれに関連する疾患の治療及び予防のためのプロバイオティック微生物の使用
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
EP2022502A1 (en) 2007-08-10 2009-02-11 Nestec S.A. Lactobacillus rhamnosus and weight control
FR2928935B1 (fr) * 2008-03-19 2011-05-20 Gervais Danone Sa Souche de lactobacillus rhamnosus.
EP2216035A1 (en) 2009-02-10 2010-08-11 Nestec S.A. Lactobacillus rhamnosus CNCM I-4096 and weight control
FI123157B (fi) * 2009-05-12 2012-11-30 Valio Oy Probioottien uusi käyttö
EA024911B1 (ru) 2010-01-08 2016-11-30 Компани Жервэ Данон Лактобациллы с антиоксидантным действием
WO2011148219A1 (en) 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving the enteric nervous system

Also Published As

Publication number Publication date
US9855304B2 (en) 2018-01-02
WO2014072771A1 (en) 2014-05-15
BR112015010639A2 (pt) 2017-07-11
MX2015005897A (es) 2016-02-05
JP2016507216A (ja) 2016-03-10
CA2890574A1 (en) 2014-05-15
CN104955467A (zh) 2015-09-30
US20150283186A1 (en) 2015-10-08
RU2015122728A (ru) 2017-01-10
EP2925333A1 (en) 2015-10-07

Similar Documents

Publication Publication Date Title
SV2017005367A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
AR093426A1 (es) Uso de una cepa de lactobacillus rhamnosus para reducir la ganancia de peso o la resistencia a la insulina, o ambas cosas al mismo tiempo
BR112016018283A2 (pt) Composição que compreende bifidobacterium animalis ssp. lactis
SV2015004969A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
AR094025A1 (es) Utilizacion de bifidobacterium animalis para el tratamiento o la prevencion de la ganancia de peso corporal y de la resistencia a la insulina
DOP2013000007A (es) Pirimidinadas y triazinas condensadas y su uso
IN2015DN02826A (es)
CL2011001939A1 (es) Uso de lactobacillus helveticus cncm i-4095 para apoyar la perdida de peso y/o mantenimiento del peso en humanos y/o animales, particularmente para tratar la obesidad y trastornos metabólicos; y microorganismo de la cepa de lactobacillus helveticus cncm i-4095.
CL2013002210A1 (es) Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano.
EP3943092A3 (en) Compositions for use in inducing differentiation of human brown adipocyte progenitors
NZ711956A (en) Rice protein supplements
AR098703A1 (es) Composición alimenticia para baño de oblea para helados y método para su elaboración
AR093425A1 (es) Cepa de lactobacillus rhamnosus para reducir la acumulacion de grasa corporal
MX2017002584A (es) Composicion y producto medicinal para reducir peso corporal y grasa corporal, y uso del producto.
PT3137635T (pt) Estirpes de lactobacillus de ação rápida e sua utilização para melhoramento da estabilidade aeróbica da silagem
CL2011001937A1 (es) Uso de la cepa de lactobacillus rhamnosus cncm i-4096 para apoyar la pérdida de peso y/o mantenimiento del peso en humanos y/o animales, específicamente para el tratamiento de la obesidad.
ES2711427T8 (es) Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos
WO2015121458A3 (fr) Utilisations de compositions comprenant du bifidobacterium animalis ssp. lactis lmg p-28149
MY171048A (en) Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions
MX2017001632A (es) Mioinositol y probioticos, y uso de estos.
MX345948B (es) Uso de cepas mutantes resistentes a la nisina de lactobacilos para reducir la post-acidificación en los productos alimenticios.
CL2016001752A1 (es) Administración de vitamina b6 materna para la prevención del aumento de la adiposidad, el sobrepeso o la obesidad en la descendencia
MX2015002290A (es) Una composicion alimenticia que comprende una mezcla de permeado lacteo y harina vegetal.
SG11201804602SA (en) Nutritional composition
CR20190142A (es) Composiciones de tesofensina

Legal Events

Date Code Title Description
FB Suspension of granting procedure